Antinociceptive and anti-inflammatory effects of *Amygdalus eburnea* shell root extract in mice

Nasrin Galehdar¹, Mostafa Rezaeifar², Maryam Rezaeifar², Mehdi Rezaeifar³,*

**ABSTRACT**

**Introduction.** The current study aims to assess the antinociceptive and anti-inflammatory activities of *Amygdalus eburnea* Spach extract in mice. **Methods.** Totally, 114 NMRI mice were used in this study. The acute toxicity was evaluated for two days. The antinociceptive effect was accessed by using the hot-plate, tail-flick, and rotarod test. In this investigation, anti-inflammatory effects were evaluated by using the Xylene-induced ear edema method. The findings demonstrated that in the hot-plate and tail-flick tests, *A. eburnea* extract particularly at the dose of 750 mg/kg demonstrated a considerable analgesic effect; so that there was a significant difference between the extract-treated group and the control group (p<0.05). **Results.** The results showed that the administration of *A. eburnea* extract especially at the dose of 500 and 750 mg/kg significantly decreased the ear edema induced by xylene in comparison to the control group. There was no significant difference after injecting of various doses of *A. eburnea* extract in the sensory-motor test (p > 0.05). **Conclusion.** These results demonstrated the potent antinociceptive and anti-inflammatory effects of *A. eburnea* extract in mice. Nevertheless, the precise mechanisms responsible for these activities remain to be studied.

**Key words:** Hot-plate, Inflammation, Mice, Pain, Rotarod, Tail-flick

**INTRODUCTION**

Pain is a complex process and an unpleasant sensory experience that is usually caused by the stimulation of free nerve terminals. In another definition, pain can be said to be a vigilant experience that results from brain activity in response to harmful stimuli and involves sensory, emotional and cognitive processes that can lead to isolation, immobility, and drug dependence. Pain sometimes persists despite the removal of irritants and the improvement in the outlook at the affected sites, but pain usually disappears after the removal of the excitation sources. Generally, pain is divided into two categories: (i) acute pains are those usually accompanied with ulcers and diseases. Acute pains can be very short and transient, such as an insect bite, or may last for a long time like a burn; (ii) Chronic pains are those last more than six months from its onset, and their termination is not predictable. Unlike acute pains, which causes are usually known, causes for chronic pains may remain unknown.

Given that more than 50% of people in the world have experiences with pains, there is a constant quest for effective medications to relieve pains. Although chemical drugs that are used today to reduce pains have some desired properties, they have unwanted and harmful effects, such as gastrointestinal bleeding and cardiovascular disorders, which makes the use of these medicines dangerous. Hence, finding alternative solutions which are not only effective in relieving pain but also have minimal side effects is an essential task.

For many years, plant materials and derivatives have been considered as alternative approaches to chemical drugs. *Amygdalus eburnea* Spach with the local name “Ghosk”, is a plant of the Rosaceae family. This family includes species that are close to crop almonds and have spread from Central Asia to southern Europe, and southern parts of Iran. *A. eburnea* is in the form of trees or shrubs without thorns or small thorns and with leaves that are folded together in the bud. Besides, this plant has also been used to prevent soil erosion and to stabilize watersheds in semi-desert regions of Iran. In addition, the plant has been used as a healing agent from very early in the history to alleviate burn wounds, as well as to reduce gastrointestinal, respiratory and cough disorders, and to treat worm infection. In addition to applications in traditional medicine, in modern medicine, various properties of this plant including antioxidant, anti-bacterial and anti-fungal properties have been confirmed. Based on what has been discovered, this study aims to evaluate the antinociceptive and anti-inflammatory effects of *A. eburnea* extract in NMRI male mice.

METHODS

Plant collection
Due to the abundance of A. eburnea in rural areas of Kerman district, shell roots were collected in this area in the Southeast of Iran, during April 2013. The plant materials were received at the Herbarium of Department of Pharmacognosy, School of Pharmacy, Kerman University of Medical Science, Iran.

Preparation of the methanolic extract
Using the percolation method, approximately 100 g of dried plant material was extracted by using 80% methanol for 72 h at room temperature. To purify further, the crude extract was filtered through a filter paper. In the final step, the extract was concentrated in vacuum at 50°C by a rotary evaporator (Heidolph, Germany) and was kept at -20°C until use.

Animals
Groups of six male NMRI mice weighing from 25 to 30 gram with the same light-dark cycles (12:12-h) were used at the room temperature (21±1°C). Enough food and water were provided for mice.

Ethics
The ethical approval required for this study was issued by the Ethics Committee of Kerman University of Medical Sciences, Kerman, Iran.

Antinociceptive effects

Tail-flick test
In the tail-flick test, an intense beam of light is focused on the middle one-third of animal’s tail. In this experiment, five groups of six mice with 30 mice in total were treated with different doses of A. eburnea extract (250, 500, and 750 mg/kg) and were subjected to the tail-flick test to evaluate the terminal pain threshold. The light intensity of the tail flick apparatus (Sparco, Iran) was adjusted to make a 2 to 4 s latency time in the control animal. A 10-second cutoff time was chosen to prevent any possible tissue damage. Latency time was recorded three times with a 15-min interval for each set of the tail-flick test; the mean value of the latency time was considered as the thermal pain threshold (tail flick latency).

Hot-plate test
The plate temperature of the device was set to 55±0.2°C to evaluate pain sensitivity of the mice treated with different doses of A. eburnea extract (250, 500, and 750 mg/kg), normal saline, or morphine. The apparatus contained a plate with the diameter of 19 cm and a Plexiglas wall with the height of 30 cm (LE710 model, Lsi LETICA, Spain). The interval between the start of the experiment and the licking front paw or jumping was measured as the reaction time to thermal pain (maximum cutoff was considered 60s).

Anti-inflammatory study

Xylene-induced ear edema
In this investigation, anti-inflammatory effects of were evaluated using the xylene-induced ear edema method which was described in earlier studies. Briefly, 30 mice were randomly divided into five groups (six mice in each group). One hour after the IP administration of the various doses of A. eburnea extract (250, 500, and 750 mg/kg), xylene was treated to the anterior surfaces of the right ear, and the left ear was used as a control. In this test, dexamethasone and normal saline were used as the positive and negative control respectively. In the next step, 120 min after the administration of xylene, mice were sacrificed and both ears were detached. 5-mm ear punch biopsies were collected and weighed. The difference between the weight of the left and the ear biopsies was considered as edema.

Rotarod test
In this study, we used the rotarod test to evaluate the motor coordination in tested animals. Before testing, mice were trained to stay for three min on a rolling rod (3 cm, diameter) rotating at 8 rpm. At the time of the test, three groups (six mice in each) were treated with different doses of A. eburnea extract (250, 500, and 750 mg/kg) and one group was treated with normal saline as the negative control. Finally, after the administration of A. eburnea extract and normal saline, mice were placed on the rolling rod, and the number of falls experienced by the mice during the procedure (three minutes) was recorded.

Statistical analysis
The results of the experiments were analyzed by SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA). To evaluate the difference between experimental groups, one-way ANOVA test was performed using Tukey’s post-hoc test. At last, P<0.05 was considered statistically significant.
RESULTS

The analgesic effect of A. eburnea extract on tail-flick test

Figure 1 indicates the antinociceptive effects of A. eburnea extract in a dose-dependent manner in the tail-flick test. Groups treated with A. eburnea extract at the doses of 250, 500 and 750 mg/kg had a mean latency time of 4.6, 6.3 and 7.6 seconds, respectively; indicating a significant (p<0.05) antinociceptive effect compared to the control group. Although the time latency of the extract at the dose of 750 mg/kg was more than morphine, no significant difference was observed (p>0.05).

The analgesic effect of A. eburnea extract on hot-plate test

According to Figure 2, A. eburnea extract at the doses of 250, 500 and 750 mg/kg had a potent antinociceptive effect in a dose-dependent manner. The results showed a significant difference between the saline- and extract-treated groups (p<0.05). The reaction time of the extract-treated groups at the doses of 250, 500, and 750 mg/kg was 16.3, 21.6, and 26.6 seconds, respectively; Although the reaction time at the dose 750 mg/kg was more than that of morphine (24.3s), there was no significant difference between the two groups (p>0.05).

Effects of A. eburnea extract on xylene-induced ear edema in mice

Table 1 shows the findings obtained from the xylene-induced mice ear edema experiment. The results showed that the administration of A. eburnea extract at the doses 250, 500 and 750 mg/kg significantly decreased the ear edema induced by xylene compared to the control group in tested mice (21.5, 50.9, and 69.6%, respectively). Whereas, dexamethasone at the dose of 10 mg/kg reduced the ear edema induced by xylene up to 66.9% in tested animals.

Rotarod test

In this study, the motor coordination after administration of the various doses of A. eburnea extract in tested animals was evaluated using the rotarod test. The obtained results showed that there is no significant (p>0.05) change in the sensory-motor test after the administration of A. eburnea extract at the doses of 250, 500 and 750 mg/kg.

DISCUSSION

Today, pain is considered one of the most widespread concerns with considerable social and economic impacts. Everyone may have experienced a variety of pains such as nociceptive, inflammatory, neuropathic, and functional pains which are caused by various neurological mechanisms. Although a number of analgesic medications are available to remedy a broad spectrum of pain and inflammation, such as non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids and opioids, their adverse side effects and also ineffectiveness of some medications for particular conditions necessitate the constant investigation for new pain relievers.

Recent studies demonstrated that plants and their products are vital sources to find proper and less toxic reagents. In modern medicine, the ethnobotanical studies have revealed different medicinal possessions of herbal such as antinociceptive, anti-inflammatory, anti-cancer, and antimicrobial effects. To the best of our knowledge, a wide range of medicinal herbs such as Citrullus colocynthis, Carcuma longa, Crocus sativus, Elaeagnus angustifolia, Ginkgo biloba, Mitragyna speciosa, Momordica charantia, Nigella sativa, Ocimum sanctum, Phyllanthus amarus, Zataria multiflora, Crocus sativus, Zhameria majdae, Elaeagnus angustifolia, Urtica pilulifera, and Rosa damascene are well-known as analgesic in modern medicine. Therefore, this study aims to evaluate the antinociceptive and anti-inflammatory effects of A. eburnea extract using the tail-flick and hot-plate tests in NMRI mice.

The obtained findings in the tail-flick and hot-plate tests demonstrated that A. eburnea extract at the doses of 250, 500 and 750 mg/kg had a potent antinociceptive effect in a dose-dependent manner. The results showed a significant difference the saline- and extract-treated groups (p<0.05). The reaction time of the extract-treated groups at the dose of 750 mg/kg was more than that of morphine, but there was no significant difference between them (p>0.05).

One of the main tests to evaluate the antinociceptive effects of tested agents is the hot-plate test. We found that the A. eburnea extract had a dose-dependent response in reducing heat-induced pain. Subsequently, the tail-flick test is applied to study the spinal responses and to detect the central analgesic route; this extract may induce its analgesic effect through the central nervous system. On the other hand, in the hot-plate test, A. eburnea extract demonstrated an analgesic effect based on a dose-dependent manner; so there was a significant difference between...
**Figure 1:** Effect of the *A. eburnea* extract and morphine on the pain threshold of the mice in the tail-flick test.

**Figure 2:** Effect of the *A. eburnea* extract and morphine on the pain threshold of the mice in the hot plate test.

**Table 1:** Anti-inflammatory effect of *A. eburnea* extract in xylene-induced ear edema in mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Edema weight (mg)</th>
<th>% Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (normal saline)</td>
<td>11.2 ± 0.6</td>
<td></td>
</tr>
<tr>
<td><em>A. eburnea</em> extract (250 mg/kg)</td>
<td>8.8 ± 1.15</td>
<td>21.5</td>
</tr>
<tr>
<td><em>A. eburnea</em> extract (500 mg/kg)</td>
<td>5.5 ± 0.51</td>
<td>50.9*</td>
</tr>
<tr>
<td><em>A. eburnea</em> extract (750 mg/kg)</td>
<td>3.4 ± 0.5</td>
<td>69.6*</td>
</tr>
<tr>
<td>Dexamethsone (10 mg/kg)</td>
<td>3.7 ± 0.15</td>
<td>66.9</td>
</tr>
</tbody>
</table>
the extract-treated groups and saline-treated group (p<0.05). These results also showed that the antinociceptive effect in the extract-treated group at the dose of 750 mg/kg was more potent than that of morphine. However, this difference was not significant. These findings suggested that *A. eburnea* probably showed antinociceptive effects via the central opioid receptors or an increase in the release of endogenous opioid peptides\(^{23,24}\).

Regarding the anti-inflammatory effect of *A. eburnea* extract, we found that the administration of *A. eburnea* extract especially at the doses of 50 and 750 mg/kg significantly decreased the ear edema induced by xylene compared to the control group in tested mice. Regarding the antinociceptive and anti-inflammatory effects of plants in Rosaceae family, there are few studies, for example, Vongtau *et al* 2004 demonstrated the *Parinari polyandra* methanolic extract have considerable anti-inflammatory and anti-nociceptive effect particularly at the dose of 200 mg/kg in mice and rats\(^{25}\). In the other study, Mahmoodi *et al* (2016) showed that *Potentillareptans* extract at the doses of 50 and 100 mg/kg have remarkable analgesic effects compared to the control group\(^{26}\). Based on the previous studies, in phytochemical screening of plants in Rosaceae family, the presence of flavonoids, tannins, and saponin glycoside have been proven\(^{27}\). Since the antinociceptive and anti-inflammatory effects of these compounds have been shown\(^{28,29}\); a number of studies have shown that flavonoids and tannins components in the plants in Rosaceae family showed their antinociceptive effects through opioid receptors, nitric oxide pathway as well as via the inhibition of vanilloid receptors and the glutamatergic system\(^ {30,31}\). Therefore, it is probably that the antinociceptive and anti-inflammatory effects of *A. eburnea* may be related to the presence of these compounds.

**CONCLUSION**

There are some limitations in this study such as there was no phytochemical analysis of *A. eburnean* extract, or no other analgesic and anti-inflammatory test such as formalin test was used. The results demonstrated that *A. eburnea* extract has potent antinociceptive and anti-inflammatory effects in mice. Nevertheless, the precise mechanisms responsible for these effects remain to be studied.

**COMPETING INTERESTS**

No conflict of interest to declare.

**AUTHORS’ CONTRIBUTIONS**

Nasrin Galehdar: Study design, writing
Mostafa Rezaefar: Data collection and experiments.
Maryam Rezaefar: Data analysis
Mehdi Rezaefar: Supervisor, writing

**ACKNOWLEDGMENTS**

The authors thank from the staff of Pharmaceutic Research Center, Kerman University of Medical Sciences, Kerman, Iran.

**REFERENCES**


